San Francisco September 6, 2018 The global alzheimer’s therapeutics market is expected to reach USD 6.4 billion in 2024,
according to a new report by Grand View Research. Some primary factors driving
the market growth includes rising government initiatives in order to raise
awareness levels among people.
Growing knowledge about the Alzheimer’s
disease (AD) and its high prevalence and incidence in developing economies are
few of the major drivers supporting the market growth. Several governments,
nonprofit, and private organizations worldwide are actively engaged in
increasing people’s awareness regarding progressive AD, such as Alzheimer’s
Association, the Alzheimer’s Society of Canada, Alzheimer’s Europe
organization, and various other small organizations.
Furthermore, the increased government
funding for providing better care and support to the people with partial
dementia is another important factor anticipated to enlarge market growth. For
instance, organizations like Florida Department of Health, the National
Institute of Health, and Alzheimer’s Association in partnership with other
private and government organizations provide funds to the research centers.
The presence of various pipeline drugs is
anticipated to provide the market with potential growth opportunities. For
instance, LMTX by TauRx Pharmaceutical Ltd.; idalopirdine (Lu AE58054) by
Lundbeck; crenezumab by AC Immune SA; and BAN2401 by Eisai
Moreover, novel therapeutics with minimal
dosage requirement has been introduced resulting in cost-effective
alternatives, which is further expected to boost the market growth. For
instance, Namzaric by Actavis was developed in two forms: 10 mg and 28 mg. 10
mg requires to be administered twice a day, while 28 mg requires to be
administered once in a day.
Full Research Report On Alzheimer’s Therapeutics Market Analysis:
www.grandviewresearch.com/industry-analysis/alzheimers-therapeutics-market
www.grandviewresearch.com/industry-analysis/alzheimers-therapeutics-market
Further Key Findings from the Study Suggest:
·
The cholinesterase inhibitors
segment was dominant in 2013 but lost hold on the market till 2015. Patent
expiry of key drugs such as Aricept, Exelon, and Razadyne was the major factor
for decline in market share.
·
Exelon transdermal patch is
estimated to lose exclusivity in 2019. It is a highly prescribed drug for the
treatment of mild to moderate AD, which contributed toward its revenue
generation in 2015.
·
N-methyl-D-aspartate
receptor antagonist, on the other hand, is expected to witness a significant
growth of around 16.0% over the forecast period owing to introduction of
extended relase formulation of Namenda.
·
Other drug therapies such as
monocloclonal antibodies and drugs targeting Tau proteins are in being studied
in latter phases of the clinical trials. Presence of a strong of pipeline drugs
for target disease are attributing toward fastest growth of these drugs
·
North America dominated the
overall market in terms of revenue with share of over 33.0% in 2015, which is
majorly facilitated by the availability of sophisticated healthcare facilities
and infrastructure.
·
Some key players operating in
this industry are Pfizer, Inc.; Merck & Co. Inc.; Novartis AG; Eisai Co.
Ltd., H. Lundbeck A/S, AC Immune; TauRx Pharmaceuticals Ltd.; Actavis plc.;
Forest Laboratories; and Teva Pharmaceuticals Industries Ltd.
·
Market players are expanding
their product portfolio by developing and launching generic versions of drugs
to sustain its market position. For instance, in 2015, Dr. Reddy’s Laboratories
Ltd. and Mylan launched the generic version of Namenda (Forest laboratories –
Actavis).
View More Reports Of This Category By Grand View Research
At: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
Alzheimer’s therapeutics market on the basis of drug class and region:
Alzheimer’s Therapeutics Market Drug Outlook (Market
Revenue in USD Million, 2013 - 2024)
·
Cholinesterase Inhibitors
·
N-methyl-D-aspartate (NMDA)
receptor antagonist
Alzheimer’s Therapeutics Market Regional Outlook, (Market
Revenue in USD Million, 2013 - 2024)
·
North America
o U.S.
o Canada
·
Europe
o UK
o Germany
·
Asia Pacific
o China
o Japan
·
Latin America
o Brazil
o Mexico
·
MEA
o South Africa
Access
Full Press Release of this Report
About
Grand View Research
Grand View
Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/